Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients’ Survival
Table 1
Donor and recipient population demographics.
Parameters
Recipients,
Recipients: age at baseline, years
41 ± 10
Gender, male versus female, n (%)
26 (57.8)/19 (42.2)†
Weight, kg
73.0 ± 15.7
Cause of ESRD, n (%)
Glomerulonephritis
37 (82.3)
Polycystic kidney disease
4 (8.9)
Pyelonephritis/interstitial nephritis
2 (4.4)
Diabetic nephropathy
1 (2.2)
Congenital urological anomaly
1 (2.2)
Dialysis modality: hemodialysis versus peritoneal dialysis, n (%)
42 (93.3)/3 (6.7)
Duration of dialysis treatment, months
27.3 ± 24.9
Treated hypertension at baseline, n (%)
23 (51.1)
Previous transplants, n (%)
2 (4.4)
Previous blood transfusions, n (%)
8 (17.8)
Previous pregnancies, n (%)
5 (11.1)
Calcineurin inhibitor used initially, CsA versus tacrolimus, n (%)
44 (97.8)/1 (2.2)
Anti-CD25 antibodies use, n (%)
36 (80.0)
Donors: deceased versus living related, n (%)
21 (77.8)/6 (22.2)
Age (years) deceased
37 (30–47)
Living related
50 (45–58)
Cause of deceased donor death, stroke versus brain injury, n (%)
11 (52.4)/10 (47.6)
Heart-beating versus non-heart-beating deceased donors, n (%)
17 (81.0)/4 (19.0)
CIT (hours) deceased/living related donors
15 (13–18)/1 (1–1)‡
Second warm ischemia time, minutes
20 (18–23)
ESRD: end-stage renal disease; CsA: cyclosporine A; n: number of patients investigated; CIT: cold ischemia time. Mean ± standard deviation; †numbers (percentages); ‡median (interquartile range).
